Skip to main content
Premium Trial:

Request an Annual Quote

Illumina s Revenues Soar, Losses Narrow in Q2

NEW YORK, July 16 (GenomeWeb News) - Illumina reported a steep increase in revenues and smaller losses for the second quarter of 2004 this week.


Revenues for the quarter were $11.5 million, up from $4.8 million during the same period last year.


Research and development costs declined slightly, to $5.3 million, from $6.2 million during the same quarter a year ago.


The company's net loss amounted to $3.5 million, or $.1 per share, down from $8.6 million, or $.27 per share, during the second quarter of 2003.


As of June 27, Illumina had $66.2 million in cash and investments, of which $12.1 million were short term restricted investments.


Tim Kish, the company's CFO, said in a statement that "we remain well positioned to reach breakeven early in 2005."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.